Using Myeloid Therapeutic's breakthrough science to stop the COVID-19 pandemic!

Installing Critical Signals at Crucial Intersections of the Immune System

Located in Cambridge, MA

MYELOID TEAM

Scientific Innovators, Clinical Experts, and Corporate Leaders

 

Sophia sending Vale research

We are developing novel approaches to reprogram the body’s innate immune system to eradicate harmful and lethal diseases

 

Our team is comprised of corporate veterans and leading experts in oncology, virology, immunology, cell therapy, and clinical development. We have brought together leaders with a proven biotechnology and pharmaceutical development record who are passionate about getting powerful treatments to patients. Our mission is simple: provide novel therapies to patients with the highest unmet medical needs.


Myeloid Therapeutics is located at the biotech research center of the world in Cambridge, MA

 

 

Prof. Alberto Montavani - Tumor Macrophage Discoverer


Alberto Montavani is a Scientific Director of Istituto Clinico Humanitas (Humanitas Clinical and Research Center), President and Founder of the Fondazione Humanitas per la Ricerca, and Professor of Pathology at the State University of Milan. He is known for his works in the roles of the immune system in the development of cancer. His research on tumor-associated macrophages (TAM, an acronym he coined) established inflammation as one of the causes of cancer. He was the first to identify monocyte chemotactic protein - 1 / CCL2 in 1983, and PTX3 in 1997. His works revealed the existence of decoy receptors in cell-signalling. He has been the most cited scientist in Italy, and one of the ten most cited immunologists worldwide.




Prof. Miriam Merad, MD, PhD – Macrophage & TME Immunologist


Miriam Merad, MD, PhD is a Professor of Oncological Science, Medicine (Hem/Onc division) and Immunology and a member of the Immunology Institute and The Tisch Cancer Institute at the Mount Sinai School of Medicine in New York. Dr. Merad obtained her MD at the University of Algiers, Algeria. She did her residency in Hematology and Oncology in Paris, France and obtained her PhD in Immunology in collaboration between Stanford University and University of Paris VII. She was recruited to Mount Sinai in 2004 and was promoted to the rank of Associate Professor with Tenure in 2007 and to Full Professor in 2010 and obtained an Endowed Chair in Cancer Immunology in 2014.

In 2010 Dr. Merad became the program leader of the Cancer Immunology Immunotherapy group at The Tisch Cancer Institute and the director of the Human Immunomonitoring Center. Dr. Merad’s laboratory studies the mechanisms that regulate the development and function of the mononuclear phagocyte lineage including dendritic cells and macrophages. Her laboratory has made seminal discoveries in macrophage biology revealing their embryonic origin and their local maintenance in situ. Dr. Merad identified many of the mechanisms that control dendritic cells and macrophage development, homeostasis and function in different tissues including the contribution of mononuclear phagocytes to neuronal function, barrier tissue integrity and tumor response to immunotherapy. Dr. Merad belongs to several NIH funded scientific consortia including the mucosal immunology study team and the Immgen Consortia to decipher the transcriptional regulation of the tissue dendritic cell and macrophage lineage. Currently, one of the major goals of her laboratory is to identify the contribution of phagocytes to tumor progression and response to treatment in mice and humans.

Dr. Merad has authored more than 150 primary papers and reviews in high profile journals and has obtained extensive NIH funding for her studies on innate immunity in mice and humans.




Prof. Siamon Gordon, MD, PhD – Discovery of Scavenger Receptor


Siamon Gordon was born in South Africa, graduated in medicine at the University of Cape Town in 1961 and completed a doctorate in life sciences at Rockefeller University in 1971.Inspired by his research supervisor, Zanvil A Cohn, he has studied macrophage immunobiology over the past 50 years, first at Rockefeller, later at the Sir William Dunn School of Pathology from 1976-2008.He was elected to Fellowship of the Royal Society in 2007. His interests include the history of immunology and promoting science in South Africa, where he initiated an HIV education programme.




Prof. Nick King, MD PhD – Virus & Myeloid Cell Expert


Professor King is internationally recognized for his research on viral pathogenesis and immune-pathology and is co-inventor of the Cour immune modifying particle technology platform. He is Professor of Pathology at The University of Sydney, in Sydney Australia. He received his Bachelor of Medicine/Bachelor of Surgery from the University of Cape Town in 1976, and his PhD in 1986 from the Australian National University. After completing his post-doctoral training at the University of Sydney, he joined the department of Pathology at the University in 1988. Most recently, Prof. King was admitted as an honorary member to the Royal College of Pathologists (2009). Prof. King has held or currently holds positions as the President of Federation of Immunological Societies Asia-Oceania (FIMSA), Treasurer of the International Union of Immunology Societies, and Director of The Advanced Cytometry Facility (ACF) at the University, the most advanced and largest flow cytometry unit in the Southern Hemisphere.

His work has provided ground-breaking insights into virus-host interactions. His early work discovered the ability of viruses, like West Nile Virus to hijack cellular machinery to trick the immune system. More recently he has pioneered new understanding surrounding immune pathology observed in the brain after infection and during autoimmunity. Most recently he has focused his efforts on translating the novel discovery that nanoparticles may be harnessed to prevent immune mediated pathology. This includes the development of a phase 1/2 encephalitis clinical programs.




Michael Dee Gunn, MD - T cell Vaccine Biologist


Michael Gunn’s focus is on understanding how dendritic cells, monocytes, and macrophages regulate immune responses, contribute to specific disease pathologies, and can be manipulated to stimulate or inhibit specific immune responses. He uses his knowledge of immunology to develop diagnostics and therapeutics for a variety of human diseases. Professor of Medicine, Professor in Immunology, Assoc. Prof. in Pathology




Prof. Michael Lin, PhD – Assoc. Prof. Stanford University


Our lab applies biochemical and engineering principles to the development of protein-based tools for imaging and control of biochemical processes. Topics of investigation include fluorescent proteins structure and biophysics, fluorescent protein-based biosensors, neuronal activity sensors, spatiotemporal analysis of protein translation pathways, chemical control of protein translation, and light-responsive proteins. Associate Professor of Neurobiology, of Bioengineering and, by courtesy, of Chemical and Systems Biology





Immunology, Virology & Myeloid Cell Leadership

Clinical Cell

Therapy Leadership

Prof. Alberto Montavani - Tumor Macrophage Discoverer


Alberto Montavani is a Scientific Director of Istituto Clinico Humanitas (Humanitas Clinical and Research Center), President and Founder of the Fondazione Humanitas per la Ricerca, and Professor of Pathology at the State University of Milan. He is known for his works in the roles of the immune system in the development of cancer. His research on tumor-associated macrophages (TAM, an acronym he coined) established inflammation as one of the causes of cancer. He was the first to identify monocyte chemotactic protein - 1 / CCL2 in 1983, and PTX3 in 1997. His works revealed the existence of decoy receptors in cell-signalling. He has been the most cited scientist in Italy, and one of the ten most cited immunologists worldwide.




Prof. Miriam Merad, MD, PhD – Macrophage & TME Immunologist


Miriam Merad, MD, PhD is a Professor of Oncological Science, Medicine (Hem/Onc division) and Immunology and a member of the Immunology Institute and The Tisch Cancer Institute at the Mount Sinai School of Medicine in New York. Dr. Merad obtained her MD at the University of Algiers, Algeria. She did her residency in Hematology and Oncology in Paris, France and obtained her PhD in Immunology in collaboration between Stanford University and University of Paris VII. She was recruited to Mount Sinai in 2004 and was promoted to the rank of Associate Professor with Tenure in 2007 and to Full Professor in 2010 and obtained an Endowed Chair in Cancer Immunology in 2014.

In 2010 Dr. Merad became the program leader of the Cancer Immunology Immunotherapy group at The Tisch Cancer Institute and the director of the Human Immunomonitoring Center. Dr. Merad’s laboratory studies the mechanisms that regulate the development and function of the mononuclear phagocyte lineage including dendritic cells and macrophages. Her laboratory has made seminal discoveries in macrophage biology revealing their embryonic origin and their local maintenance in situ. Dr. Merad identified many of the mechanisms that control dendritic cells and macrophage development, homeostasis and function in different tissues including the contribution of mononuclear phagocytes to neuronal function, barrier tissue integrity and tumor response to immunotherapy. Dr. Merad belongs to several NIH funded scientific consortia including the mucosal immunology study team and the Immgen Consortia to decipher the transcriptional regulation of the tissue dendritic cell and macrophage lineage. Currently, one of the major goals of her laboratory is to identify the contribution of phagocytes to tumor progression and response to treatment in mice and humans.

Dr. Merad has authored more than 150 primary papers and reviews in high profile journals and has obtained extensive NIH funding for her studies on innate immunity in mice and humans.




Prof. Siamon Gordon, MD, PhD – Discovery of Scavenger Receptor


Siamon Gordon was born in South Africa, graduated in medicine at the University of Cape Town in 1961 and completed a doctorate in life sciences at Rockefeller University in 1971.Inspired by his research supervisor, Zanvil A Cohn, he has studied macrophage immunobiology over the past 50 years, first at Rockefeller, later at the Sir William Dunn School of Pathology from 1976-2008.He was elected to Fellowship of the Royal Society in 2007. His interests include the history of immunology and promoting science in South Africa, where he initiated an HIV education programme.




Prof. Nick King, MD PhD – Virus & Myeloid Cell Expert


Professor King is internationally recognized for his research on viral pathogenesis and immune-pathology and is co-inventor of the Cour immune modifying particle technology platform. He is Professor of Pathology at The University of Sydney, in Sydney Australia. He received his Bachelor of Medicine/Bachelor of Surgery from the University of Cape Town in 1976, and his PhD in 1986 from the Australian National University. After completing his post-doctoral training at the University of Sydney, he joined the department of Pathology at the University in 1988. Most recently, Prof. King was admitted as an honorary member to the Royal College of Pathologists (2009). Prof. King has held or currently holds positions as the President of Federation of Immunological Societies Asia-Oceania (FIMSA), Treasurer of the International Union of Immunology Societies, and Director of The Advanced Cytometry Facility (ACF) at the University, the most advanced and largest flow cytometry unit in the Southern Hemisphere.

His work has provided ground-breaking insights into virus-host interactions. His early work discovered the ability of viruses, like West Nile Virus to hijack cellular machinery to trick the immune system. More recently he has pioneered new understanding surrounding immune pathology observed in the brain after infection and during autoimmunity. Most recently he has focused his efforts on translating the novel discovery that nanoparticles may be harnessed to prevent immune mediated pathology. This includes the development of a phase 1/2 encephalitis clinical programs.




Michael Dee Gunn, MD - T cell Vaccine Biologist


Michael Gunn’s focus is on understanding how dendritic cells, monocytes, and macrophages regulate immune responses, contribute to specific disease pathologies, and can be manipulated to stimulate or inhibit specific immune responses. He uses his knowledge of immunology to develop diagnostics and therapeutics for a variety of human diseases. Professor of Medicine, Professor in Immunology, Assoc. Prof. in Pathology




Prof. Michael Lin, PhD – Assoc. Prof. Stanford University


Our lab applies biochemical and engineering principles to the development of protein-based tools for imaging and control of biochemical processes. Topics of investigation include fluorescent proteins structure and biophysics, fluorescent protein-based biosensors, neuronal activity sensors, spatiotemporal analysis of protein translation pathways, chemical control of protein translation, and light-responsive proteins. Associate Professor of Neurobiology, of Bioengineering and, by courtesy, of Chemical and Systems Biology





Research & Development Team

Yuxiao Wang PhD – Co-Founder & Assoc. Director of Discovery Research

Namita Bassaria PhD – Senior Scientist-RNA biology

Patrick Tavares MS – Scientist- Process & Discovery Research

Tyler Nicholson – Research Associate- Molecular Biology

Translational Development Team

Thomas Prod'homme PhD – Senior Director of Translational Medicine

Kyong-Rim Kieffer-Kwon PhD – Principal Scientist

Operations

Sophia Mansora – Executive Assistant & Operations

 
 

SCIENTIFIC ADVISORY BOARD

INVESTMENT

PARTNERS

Ronald Vale, PhD, Founder

Howard Hughes Medical Institute

Siddhartha Mukherjee, MD, DPhil, Founder and Chair of Advisory Board

Columbia University

Prof. Alberto Montavani, Tumor Macrophage Discover

Humanitas University

Prof. Siamon Gordon, MD, PhD, Discovery of Scavenger Receptor

University of Oxford

Prof. Michael Dee Gunn, T Cell Vaccine Biologist

Duke University

Nick King, MD, PhD, Viral Immunopathologist

The University of Sydney

Prof. Cameron Turtle, MD, PhD, T Cell Therapy Expert

Fred Hutch

Ira Mellman, PhD, Dendritic Cell Expert

Genetech

8VC-logo-black.png
Hatteras_RGB_Horz_Logo_blk_Small.png
AlexandriaRealEstateEquities-Inc-logo.jp

© 2020,   Myeloid Therapeutics.  All rights reserved.

  • LinkedIn
  • Instagram
  • Twitter

GET IN

TOUCH

300 Technology Square, Suite 203  Cambridge, MA 02139